These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35088543)

  • 21. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation.
    Sourianarayanane A; Arikapudi S; McCullough AJ; Humar A
    Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):481-487. PubMed ID: 28253211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease.
    Bhagat V; Mindikoglu AL; Nudo CG; Schiff ER; Tzakis A; Regev A
    Liver Transpl; 2009 Dec; 15(12):1814-20. PubMed ID: 19938128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stratifying Mortality in a Model for End-Stage Liver Disease Waiting List: A Brazilian Single-Center Study.
    Martino RB; Waisberg DR; Dias APM; Inoue VBS; Arantes RM; Haddad LBP; Andraus W; Lopes LD; Galvão FHF; Song ATW; D'Albuquerque LAC
    Transplant Proc; 2018 Apr; 50(3):758-761. PubMed ID: 29661431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand.
    Calzadilla-Bertot L; Jeffrey GP; Jacques B; McCaughan G; Crawford M; Angus P; Jones R; Gane E; Munn S; Macdonald G; Fawcett J; Wigg A; Chen J; Fink M; Adams LA
    Liver Transpl; 2019 Jan; 25(1):25-34. PubMed ID: 30609187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients.
    Danford CJ; Iriana S; Shen C; Curry MP; Lai M
    Liver Int; 2019 Jun; 39(6):1165-1173. PubMed ID: 30809932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
    Tan HK; Teng MLP; Soh AYS; Cheo SHY; Fook-Chong S; Goh GBB; Tan CK; Wong GW; Lee GH; Chang JPE
    Am J Gastroenterol; 2021 Jul; 116(7):1437-1446. PubMed ID: 33834737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States.
    Singal AK; Hasanin M; Kaif M; Wiesner R; Kuo YF
    Transplantation; 2016 Mar; 100(3):607-12. PubMed ID: 26479282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation.
    Tsochatzis E; Coilly A; Nadalin S; Levistky J; Tokat Y; Ghobrial M; Klinck J; Berenguer M
    Transplantation; 2019 Jan; 103(1):45-56. PubMed ID: 30153225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation.
    Tokodai K; Karadagi A; Kjaernet F; Romano A; Ericzon BG; Nowak G
    Scand J Gastroenterol; 2019 Feb; 54(2):233-239. PubMed ID: 30999770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
    Patel YA; Berg CL; Moylan CA
    Dig Dis Sci; 2016 May; 61(5):1406-16. PubMed ID: 26815171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretransplant Sarcopenia in Patients With NASH Cirrhosis Does Not Impact Rehospitalization or Mortality.
    Aby ES; Lee E; Saggi SS; Viramontes MR; Grotts JF; Agopian VG; Busuttil RW; Saab S
    J Clin Gastroenterol; 2019 Oct; 53(9):680-685. PubMed ID: 30180152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation.
    Nagpal SJ; Kabbany MN; Mohamad B; Lopez R; Zein NN; Alkhouri N
    Dig Dis Sci; 2016 Jul; 61(7):2102-7. PubMed ID: 26993824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.
    Younossi ZM; Stepanova M; Ong J; Trimble G; AlQahtani S; Younossi I; Ahmed A; Racila A; Henry L
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):580-589.e5. PubMed ID: 32531342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
    Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
    HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Liver Transplantation in Patients With Preexisting Coronary Artery Disease.
    Reznicek E; Sasaki K; Montane B; Sims A; Beard J; Fares M; Sharma V; Cywinski J; Quintini C; Aucejo FN; Eghtesad B; Miller CM; Menon KVN
    Transplantation; 2023 Apr; 107(4):933-940. PubMed ID: 36397734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting the outcome of liver transplantation in patients with non-alcoholic steatohepatitis cirrhosis: The NASH LT risk-benefit calculator.
    Karnam RS; Punchhi G; Mitsakakis N; Chen S; Saracino G; Lilly L; Asrani SK; Bhat M
    Clin Transplant; 2023 Apr; 37(4):e14930. PubMed ID: 36762716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants.
    O'Leary JG; Landaverde C; Jennings L; Goldstein RM; Davis GL
    Clin Gastroenterol Hepatol; 2011 Aug; 9(8):700-704.e1. PubMed ID: 21570483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
    Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
    JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of the Model for End-Stage Liver Disease (MELD) score to predict 1-year survival of Japanese patients with cirrhosis and to determine who will benefit from living donor liver transplantation.
    Ishigami M; Honda T; Okumura A; Ishikawa T; Kobayashi M; Katano Y; Fujimoto Y; Kiuchi T; Goto H
    J Gastroenterol; 2008; 43(5):363-8. PubMed ID: 18592154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic steatohepatitis in donors for living donor liver transplantation.
    Yamamoto K; Takada Y; Fujimoto Y; Haga H; Oike F; Kobayashi N; Tanaka K
    Transplantation; 2007 Feb; 83(3):257-62. PubMed ID: 17297396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.